Stryker reported third-quarter 2026 revenue of $6.520 billion and net income of $753 million, and announced a $29.3 million goodwill impairment and a downward revision to its full-year EPS outlook.
Stryker revised its earnings outlook downward in its third-quarter 2026 results despite expanded adoption and a more diversified product lineup. Alongside the results, the company indicated that fluctuations in global demand and execution challenges were affecting earnings.
The figures released this time were revenue of $6.520 billion and net income of $753 million. The company also disclosed that it had recognized a $293 million goodwill impairment against a backdrop of related cost increases and business efficiency challenges. Its full-year earnings per share outlook was also revised downward.
Over the longer term, the company released a scenario projecting revenue of $32.9 billion and profit of $770 million by 2029, with annual growth of 7.7% in revenue and an improvement in profit from the current approximately $3.6 billion to $4.1 billion.
From another perspective, the analysis points to the company's high dependence on its hip and knee businesses and suggests that the impairment and downward revision to the outlook could also affect previous forecasts.
Overall, the view is that, in the short term, stable procedure volumes and the resolution of bottlenecks will be the main factors affecting earnings.